11/12/2025
Recent studies suggest that hormone therapy benefits outweigh the risks for most women in perimenopause and menopause, particularly with forms of hormones available now that include first line bioidentical estrogen and progesterone, which are different than the hormones studied in earlier studies. Your midwife is happy to help you assess the risks and benefits of treatment in perimenopause or menopause for you, in the context of your symptoms and medical history.
Background:
In the 1990s, a large study called the Women’s Health Initiative was undertaken to look at estrogen-progestin therapy, and in 2002 the trial announced that estrogen-progestin therapy was being halted prematurely due to safety concerns, primarily breast cancer rates and stroke rates in some study participants. Prescriptions for menopausal hormone therapy (MHT) went down dramatically, and new physicians and providers like midwives experienced limited education around hormone therapy. The FDA warnings were attached then and have not been removed until now, though further research shows the warnings do not apply to all products equally and can dissuade patients from therapy they may benefit from.